Aptar Pharma launches eDose Counter for MDIs integrating a proprietary sensing technology
eDose Counter for MDIs
Picture courtesy of Aptar Pharma
Aptar Pharma unveils its eDose Counter for metered dose inhalers (MDIs). Our patented eDose Counter for MDIs is designed to be easy-to-use and reliable, and contributes to patient compliance. Our unique sensing technology offers direct detection of the spray, which eliminates risks of miscounting. The sensing technology is versatile and compatible with any metering valve design. In addition, our eDose Counter for MDIs includes inhaler priming and medication reminders-to-use and end-of-product-life warnings (flashing digits) while remaining cost-effective.
For further information, visit www.aptar.com/pharma
About Aptar Pharma
Aptar Pharma is part of the AptarGroup, Inc. family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage.
The company creates innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world.
Aptar Pharma provides customers with a wide range of delivery technologies and analytical services backed by decades of proven expertise.
AptarGroup is headquartered in Crystal Lake, Illinois, United States, with manufacturing facilities in North America, Europe, Asia and South America.
For more information, visitwww.aptar.com/pharma.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
